| Literature DB >> 32234020 |
Kodai Kume1, Hiroyuki Morino2, Ryosuke Miyamoto3, Yukiko Matsuda1, Ryosuke Ohsawa1, Yuhei Kanaya1, Yui Tada1, Takashi Kurashige4, Hideshi Kawakami1.
Abstract
BACKGROUND: The TWNK gene encodes the twinkle protein, which is a mitochondrial helicase for DNA replication. The dominant TWNK variants cause progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, while the recessive variants cause mitochondrial DNA depletion syndrome 7 and Perrault syndrome 5. Perrault syndrome is characterized by sensorineural hearing loss in both males and females and gonadal dysfunction in females. Patients with Perrault syndrome may present early-onset cerebellar ataxia, whereas middle-age-onset cerebellar ataxia caused by TWNK variants is rare. CASEEntities:
Keywords: Cerebellar ataxia; Perrault syndrome; TWNK
Mesh:
Substances:
Year: 2020 PMID: 32234020 PMCID: PMC7110654 DOI: 10.1186/s12881-020-01002-4
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Fig. 1Identification of the TWNK variant. a Family tree in this study. The filled circles indicate affected individuals, and the open circles and boxes indicate non-affected individuals. The proband is indicated by an arrow. b Sanger sequences of the TWNK variant in the patient and a control subject. c Domain architecture of Twinkle and previously reported variants for three phenotypes: dominant progressive external ophthalmoplegia type 3 (PEOA3); recessive mitochondrial DNA depletion syndrome 7 (MTDPS7), and Perrault syndrome 5 (PRLTS5). The variant in our case is marked in red. c Conservation of protein sequence at the nine residues with variants. Mutated residues are marked in red. The variant in our case is marked in bold
Genetic and clinical features in PRLTS5 cases
| Family | Sex | Variant | CADD | Gonadal dysfunction | Hearing loss | Cerebellar ataxia | Neuropathy | Epilepsy | Reference |
|---|---|---|---|---|---|---|---|---|---|
| I | F | p.R391H, | 22.8, 24 | + | + (13) | + (20) | N.A. | N.A. | 1 |
| F | p.R391H, | 22.8, 24 | + | + (8) | + (16) | N.A. | N.A. | 1 | |
| II | F | 29.7, 18.57 | + | + (7) | + (teens) | + (20) | + (7) | 1 | |
| F | 29.7, 18.57 | + | + (7) | + (N.A.) | + (N.A.) | N.A. | 1 | ||
| III | F | 32, 17.59 | + | + (3) | + (N.A.) | + (N.A.) | N.A. | 8 | |
| IV | F | p.R265C, p.R265C | 24.3, 24.3 | + | + (3) | + (N.A.) | + (N.A.) | N.A. | 9 |
| F | p.R265C, p.R265C | 24.3, 24.3 | + | + (3) | + (N.A.) | + (N.A.) | N.A. | 9 | |
| M | p.R265C, p.R265C | 24.3, 24.3 | N.A. | + (3) | + (N.A.) | + (N.A.) | N.A. | 9 | |
| V | F | 32, 25.3 | + | + (5) | + (3) | + (N.A.) | – | 10 | |
| F | 32, 25.3 | + | + (12) | + (11) | + (N.A.) | – | 10 | ||
| VI | F | p.R29*, p.S629F | 32, 25.3 | + | + (5) | + (35) | + (N.A.) | N.A. | 3 |
| F | p.R29*, p.S629F | 32, 25.3 | + | + (3) | + (43) | + (N.A.) | N.A. | 3 | |
| M | p.R29*, p.S629F | 32, 25.3 | N.A. | + (4) | + (20) | + (N.A.) | N.A. | 3 | |
| VII | M | 22.1, 22.1 | N.A. | + (4) | + (8) | + (N.A.) | – | 11 | |
| VIII | F | 32, 23.4 | + | + (4) | + (12) | + (N.A.) | N.A. | 12 | |
| IX | F | p.R453Q, p.R453Q | 23.4, 23.4 | N.A. | + (48) | + (53) | + (57) | N.A. | Our case |
The variants located in fully conserved amino acids in vertebrates are marked in bold. The numbers in parentheses indicate ages of onset
Abbreviations: CADD Combined Annotation Dependent Depletion, N.A. not available